Eli Lilly & Co. (LLY) Tops Q2 EPS by 16c; Updates FY15 Outlook
Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $0.90, $0.16 better than the analyst estimate of $0.74. Revenue for the quarter came in at $4.98 billion versus the consensus estimate of $4.89 billion.
The following table summarizes the company's 2015 financial guidance:
2015 Guidance | |||
Prior | Revised | ||
Revenue | $19.5 to $20.0 billion | $19.7 to $20.0 billion | |
Gross Margin % of Revenue (reported) | Approx. 74.5% | Approx. 74.5% | |
Gross Margin % of Revenue (non-GAAP) | Approx. 78.0% | Approx. 78.0% | |
Marketing, Selling & Admin (reported) | $6.4 to $6.7 billion | $6.4 to $6.7 billion | |
Marketing, Selling & Admin (non-GAAP) | $6.3 to $6.6 billion | $6.3 to $6.6 billion | |
Research & Development | $4.7 to $4.9 billion | $4.7 to $4.9 billion | |
Other Income/(Expense) (reported) | $75 to $125 million | ($50 million) to $0 | |
Other Income/(Expense) (non-GAAP) | $75 to $125 million | $100 to $150 million | |
Tax Rate (reported) | Approx. 16.5% | Approx. 14.5% | |
Tax Rate (non-GAAP) | Approx. 21.5% | Approx. 21.0% | |
Earnings per share (reported) | $2.21 to $2.31 | $2.20 to $2.30 | |
Earnings per share (non-GAAP) | $3.10 to $3.20 | $3.20 to $3.30 | |
Capital Expenditures | Approx. $1.3 billion | Approx. $1.3 billion |
*** The Street sees FY15 revenue of $19.80 billion and EPS of $3.18.
The company's 2015 financial guidance is subject to final acquisition accounting adjustments for the acquisitions of Novartis Animal Health and Erbitux rights.
For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.